EDGE ARTICLE

Check for updates

Ruthenium based antimicrobial theranostics – using nanoscopy to identify therapeutic targets and resistance mechanisms in *Staphylococcus aureus*†

Kirsty L. Smitten, ID *[ab] Simon D. Fairbanks,[a] Craig C. Robertson,[a] Jorge Bernardino de la Serna, ID [cd] Simon J. Foster ID [b] and Jim A. Thomas ID *[a]

In previous studies we reported that specific dinuclear Ru[II] complexes are particularly active against pathogenic Gram-negative bacteria and, unusually for this class of compounds, appeared to display lowered activity against Gram-positive bacteria. With the aim of identifying resistance mechanisms specific to Gram-positive bacteria, the uptake and antimicrobial activity of the lead complex against *Staphylococcus aureus* SH1000 and other isolates, including MRSA was investigated. This revealed differential, strain specific, sensitivity to the complex. Exploiting the inherent luminescent properties of the Ru[II] complex, super-resolution STED nanoscopy was used to image its initial interaction with *S. aureus* and confirm its cellular internalization. Membrane damage assays and transmission electron microscopy confirm that the complex disrupts the bacterial membrane structure before internalization, which ultimately results in a small amount of DNA damage. A known resistance mechanism against cationic antimicrobials in Gram-positive bacteria involves increased expression of the *mprF* gene as this results in an accumulation of positively charged lysyl-phosphatidylglycerol on the outer leaflet of the cytoplasmic membrane that electrostatically repel cationic species. Consistent with this model, it was found that an *mprF* deficient strain was particularly susceptible to treatment with the lead complex. More detailed co-staining studies also revealed that the complex was more active in *S. aureus* strains missing, or with altered, wall teichoic acids.

Introduction

Over the last few decades it has become increasingly clear that antimicrobial resistance, AMR, is evolving into a global crisis.[1–5] Although reports of resistance to antibiotics emerged quite soon after their rollout, the current extent and breadth of resistant infections is unprecedented and continues to rapidly increase.[6–8] Due to a combination of scientific and commercial reasons, this problem is being exacerbated by a dearth of new therapeutic leads.[9–17] Consequently, in the last few years, a series of national and international initiatives have been launched to provide the required economic pull and push to incentivize new drug discovery programs.[2,18] In terms of

chemistry, the need for leads with novel mechanisms of action to established antibiotics has driven searches into new chemical space.[19,20] In this context, the potential of metal complexes has begun to be revisited.

Even though ground-breaking studies by the Dwyer group in the mid-twentieth century had established that polypyridyl complexes of mid-transition metal ions display antimicrobial activity[21] – particularly against Gram-positive organisms[22] – research into metal-based leads stagnated for almost fifty years. Now, with the rise in concerns over AMR, interest in such systems is undergoing a renaissance.[23–26]

Whilst a number of reports have demonstrated that the activity of conventional antibiotics can be modulated or potentiated by connection to metal–organic fragments,[27] molecular architectures that are very different to natural systems have also been investigated.[28,29] A range of metals have been used in these studies, but – inspired by Dwyer's early work – many reports have involved Ru[II] complexes.[30–32]

In 2011, Aldrich-Wright, Bolhuis and co-workers showed that mononuclear Ru[II] complexes incorporating the DNA intercalating ligand dppz (dppz = dipyridophenazine) display promising *in vivo* activity against strains of the Gram-positive bacterium, *Staphylococcus aureus*.[33] Subsequent reports on other intercalating[34,35] and non-intercalating[36] mononuclear

[a]Department of Chemistry, University of Sheffield, Sheffield S10 2TN, UK. E-mail: ksmitten1@sheffield.ac.uk; james.thomas@sheffield.ac.uk

[b]The Florey Institute and Department of Molecular Biology and Biotechnology, University of Sheffield, S10 2TN, UK

[c]National Heart and Lung Institute, Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

[d]Research Complex at Harwell, Rutherford Appleton Laboratory, Central Laser Facility, United Kingdom Research and Innovation, OX11 0FA, UK

Ru^{II} complexes have revealed comparable activities and such studies have also been extended to oligonuclear compounds.

Inspired by work from the Kelly group,[37,38] Keene and Collins began investigating dinuclear Ru^{II} complexes with flexible linkers as probes for non-canonical DNA structures.[39,40] However, on discovering the interesting antibacterial activity of these systems,[41] their work switched focus. A series of studies on oligonuclear complexes revealed that longer, flexible linkers between metal centres produces higher activity against therapeutically resistant Gram-positive pathogens, although activity against Gram-negative pathogens is still lower.[42]

The mechanism for the selective therapeutic action of these compounds has been investigated but is still not fully established. Studies indicate that active complexes bind ribosomal RNA in prokaryotes, but it is also true that they bind RNA in the eukaryotic nucleus[43] A recent combined NMR and computational study using membrane models suggested that – due to the increased anionic charge of bacterial membranes – the complexes selectively bridge bacterial walls, but not eukaryote membranes.[44] Interestingly, these studies also showed that the bound complexes do not structurally compromise the membrane as leakage assays revealed no lytic activity.

As part of a program to identify oligonuclear complexes that recognize biologically relevant ions and biomolecules, the Thomas group has been investigating the biological properties of Ru^{II}, Os^{II}, and Ir^{III} complexes containing the rigidly planar poly-aromatic ligand tetrapyridophenazine, tpphz.[45–50] Most of this work has centred on their bio-imaging and therapeutic potential with eukaryotic cells. But – as our original report on cell imaging showed that the prototype system, [{Ru(phen)$_2$}$_2$(tpphz)]$^{4+}$, $\mathbf{1}^{4+}$, was readily taken up by *S. aureus* cells[46] – we set out to develop new dual imaging/antimicrobial theranostics based on this architecture.

In a recent paper we described the first results of these studies, identifying derivatives of $\mathbf{1}^{4+}$, Fig. 1, containing more lipophilic ancillary ligands that are active against Gram-positive and Gram-negative bacteria, including members of the multi-drug resistant ESKAPE group of pathogens.[51] Experiments on the most promising lead suggested that its therapeutic action was, at least partly, due to disruption of bacterial membrane structure. Given this distinctive spectrum of activity, we set out to explore whether $\mathbf{1}^{4+}$ and its analogues are active against the pathogen *S. aureus*. Herein, we report the X-ray crystal structure of the lead system, explore its mechanism of action and identify resistance mechanisms that explain why it is less active against Gram-positive bacteria compared to Gram-negative bacteria.

Results and discussion

Crystallographic studies

Crystals grown from *rac*-$\mathbf{4}^{4+}$ suitable for X-ray structure determination were successfully obtained by vapour diffusion of diethyl ether into a nitromethane solution of its hexafluoride salt. A summary of the crystallographic data and thermal ellipsoid plots can be found in the ESI.†

As shown in Fig. 2, coordination ligands around the ruthenium centres $\mathbf{4}^{4+}$ define the expected octahedral geometry,


Fig. 1 Complexes investigated in this study.

distorted by accommodation of three chelating ligands. The resultant Ru–N bond lengths (2.036–2.069 Å) and bite angles (79.48–80.84°) are consistent with other reported dinuclear ruthenium polypyridyl complexes, including the closely related complex [{Ru(bpy)$_2$}$_2$(tpphz)]$^{4+}$ (bpy = 2′2-bipyridine)[50,52] Although crystals were grown from *rac*-$\mathbf{4}^{4+}$ – a mixture of the Δ,Δ, Λ,Λ and Λ,Λ isomers of $\mathbf{4}^{4+}$ – the crystals shows cations packed in layers of offset coplanar stacks, where each alternating layer is solely comprised of either the Δ,Δ or Λ,Λ


Fig. 2 Crystal structure grown from *rac*-$\mathbf{4}^{4+}$. Crystal structure showing Δ,Δ and Λ,Λ layers connected by interaction. (A) Space filling representation with PF$_6$ counter ions. (B) Stick structure of $\mathbf{4}^{4+}$ without counter ions.

enantiomer. Interestingly, when $[\{Ru(bpy)_2\}_2(tpphz)]^{4+}$ was similarly crystallized from an unresolved mixture of its stereo-isomers the resulting structure also only contained the Δ,Δ and Λ,Λ forms and it was suggested that Λ,Δ form is more soluble than the enantiomeric pair.[52] Alternatively, this phenomenon may be due to crystal packing effects.

Biological studies

As discussed above, in our recent report, we investigated the uptake and therapeutic activity of 1^{4+}, 3^{4+}–5^{4+} against two examples of the pathogenic ESKAPE group of bacteria; the EC958 ST131 strain of Gram-negative *Escherichia coli* and the V583 strain of Gram-positive *Enterococcus faecalis*.[51] and found they were more active against the Gram-negative organism. Further studies showed that the most promising lead, 4^{4+}, appears to be therapeutically active through a number of mechanisms, which include structural disruption of the Gram-negative cell membranes.

These intriguing results prompted us to investigate the therapeutic action of this class of compounds against Gram-positive bacteria in more detail. For our exemplar of a typical Gram-positive microorganism we chose *S. aureus*.

Partially, this choice was prompted by the fact that we had already established 1^{4+} is readily internalized by *S. aureus*,[46] but this bacterium also provides an ideal "test-bed" to investigate potential resistance mechanisms. Apart from the fact that pathogenic *S. aureus* strains – particularly methicillin-resistant variants (MRSA), cause pernicious infections associated with treatment failure, higher morbidity/mortality rates, and prolonged hospitalizations greatly increasing health care costs[53–55] – the mechanisms of therapeutic resistance in specific strains are well studied[56–59] and so they can be used to probe the molecular mechanism of new antimicrobials. Therefore, in this study we investigate the potency of 1^{4+}–5^{4+} against a range of *S. aureus* strains. Compounds used in biological studies were the mixture of stereoisomers, not the crystallised material.

Initially, to identify the most active lead against a representative wild type strain of *S. aureus* (SH1000),[60] the minimum inhibitory concentration, MIC, of the complexes in chemically defined minimal media, CDM, and the commonly used Mueller-Hinton-II media, MH-II was obtained – Table 1. Although nutrient-rich growth media, like MH-II, are used as a standard in clinical assessments of antimicrobials, the nutrient limited environment provided by CDM also represents relevant biological conditions during different stages of infection *in vivo*.[61] As with previous studies, the complexes show increased activity in the CDM, the lower potencies in MH-II relative to the CDM is likely due to the complexes interacting with components in the complex media.

Minimum bactericidal concentrations, MBC, were also calculated for the compounds in minimal media to determined bactericidal effects – Table 2. As a compound is seen to be bactericidal if it possesses an MBC that is ≤ 4 [MIC],[62] a comparison of data indicated that all the tested compounds are bactericidal.

To confirm that these compounds are bactericidal, cell death curves were conducted at five times the MIC concentration for the two most potent compounds, 4^{4+} and 5^{4+} – see ESI.† A 3Log10 decrease (99.9%) in CFU mL^{-1} is observed, verifying their bactericidal activity.

Previous research indicated that increasing the lipophilicity of the compounds increases the activity.[41,51] This effect is apparent here: the most potent compound appears to be the only true lipophilic compound. However, such direct comparisons are misleading, as 5^{4+} precipitated at high concentrations and 5% DMSO was required to improve its solubility – see ESI† for growth curves. As 4^{4+} displays comparable potency, but without addition of DMSO, it was taken as the more promising lead and investigated in more detail.

In time-kill assays the majority of cells exposed to 4^{4+} die within 30 min. This is much faster than the oxacillin control, suggesting that the complex displays a different mechanism of action to this beta-lactam antibiotic. To investigate this rapid bactericidal effect, ICP-AES-based uptake experiments with wild-type SH1000 cells exposed to 4^{4+} at time points up to an hour were carried out – Fig. 3.

In these experiments, measurement of iron content (a trace element in all cells) was used as a control and, as expected, a negligible change in [Fe] was observed. CFU/mL readings were also taken to monitor whether cells were lysing/growing during the experiment – see ESI.†

Consistent with the rapid cell death observed in the time-kill assays, accumulation of Ru^{II} was also found to be rapid. As previous work demonstrated that 4^{4+} is taken up into Gram-negative bacteria through an active transport mechanism,[51] uptake by *S. aureus* was studied in the presence and absence of glucose over a 60 minute time course and the rates of uptake were determined (μM min^{-1}) for 4^{4+} – see ESI† – at each time point. In the absence of glucose, accumulation over 5 minutes is followed by gradual uptake to a final figure of around 2×10^{-16} g per cell; assuming an average cell volume[63,64] of 1 μm^3 this is equivalent to an intracellular concentration of >1 mM per cell.

Table 1 MIC (μM) results for *S. aureus* SH1000 in CDM and MH-II

Complex	MH-II	CDM
1^{4+}	66.7	21.3
2^{4+}	100	64
3^{4+}	50	58.7
4^{4+}	40	4
5^{4+}	20	2
Oxacillin control	2.5	2.5

Table 2 MBC (μM) results for *S. aureus* SH1000 in CDM and MH-II

| Complex	MH-II	CDM	MIC/MBC (CDM)
1^{4+}	114	58.7	2.8
2^{4+}	170	106.7	1.7
3^{4+}	100	85.3	1.5
4^{4+}	80	13.3	3.3
5^{4+}	40	6.7	3.3
Oxacillin control	2.5	2.5	2.5

Fig. 3 Accumulation experiments. ICP-AES data for the uptake of ruthenium by *S. aureus*, SH1000, after exposure to 4^{4+} in the absence (AI) and presence (AII) of glucose. Ru (blue) and Fe (red) levels per cell are exposed as metal (g) per cell. *T*-test stats are given as a comparison at each time-point (B). Fe levels were calculated as a control. Conditions: concentration of 4^{4+} = 4 μM. Cells were washed with 0.5% (v/v) nitric acid to remove unbound complex. Error bars represent three independent biological repeats ±SD.


Fig. 4 Super-resolution SIM imaging revealing localization of 4^{4+} in *S. aureus* SH1000 cells at (A) 5 min and (B) 60 min. Cells images using the emission of 4^{4+} on excitation at 450 nm using the A568 filter. After treatment with 4 μM 4^{4+}, cells were washed with PBS before fixing with paraformaldehyde (4%).

Although the uptake profile of the complex in the presence of glucose displays a similar profile in these conditions there is significantly greater intracellular accumulation of ruthenium (~3 mM per cell), suggesting that an energy-dependent active transport mechanism contributes to the uptake of 4^{4+} into SH1000 cells. However, in contrast to previously reported experiments with *E. coli*,[51] ruthenium accumulation within *S. aureus* in the absence of glucose does not take place over two phases, suggesting that the mechanism of uptake for 4^{4+} may be different in Gram-negative and Gram-positive bacteria.

Our previous microscopy experiments suggested that the compound initially binds to lipopolysaccharides on the outer membrane of *E. coli*, however *S. aureus* does not possess an outer membrane. Therefore, to study the target of 4^{4+} at the molecular scale, its cellular uptake was monitored by a super resolution technique, structure illumination microscopy, SIM, allowing for sub-diffraction resolutions of >100 nm (ref. 65 and 66) – Fig. 4.

Within 5 minutes, the majority of cells show that 4^{4+} localizes at cell membranes and within the cell cytoplasm. Accumulation of 4^{4+} is uneven, with punctate patterns. By 60 minutes the compound shows distinct foci within cells. The observation of intracellular accumulation is similar to that for *E. coli* when exposed to 4^{4+}.[51]

In recent studies we have demonstrated how complexes like 1^{4+} and its analogues can be employed as optical probes for STED, a powerful technique that can, potentially, produce resolutions equal to those of stochastic techniques such as STORM.[65,67–69] In our 3D-STED experiments, the resolution of images probing localization of 4^{4+} on the membrane of SH1000 cells was improved up to 43 nm and we regularly resolved structural patterns below 80 nm in the *XY* plane and above

150 nm in the axial plane – Fig. 5. The direct imaging of the cell septum indicated that the compound is not bound to the peptidoglycan within the cell wall; instead 4^{4+} is localized within or on the membrane. At the improved resolutions provided by 3D-STED the uneven accumulation observed using SIM is revealed to be a distinctive patterning over the entire surface of the *S. aureus* membrane.


Fig. 5 Stimulated emission depletion (STED) nanoscopy. Representative data showing section planes of full-volume cells deconvoluted diffraction-limited (d-LCSM, green) and 3D super-resolution images (Red, d-3D STED). Zoomed in areas of the white square are shown in adjacent images, as well as the orthogonal representation of every axis (*XY*, *XZ* and *YZ*), where the increased resolution and better localization of 4^{4+} is shown in red. This reveals accumulation at specific locations within the cell membrane. Conditions: after 60 minute treatment with 4 μM 4^{4+}, cells were washed with PBS before fixing with paraformaldehyde (4%).

As complexes 1^{4+}–5^{4+} are all known to bind nucleic acids[45,51] and the parent compound localizes in the nucleus of eukaryotic cells,[46] the commonly used prokaryotic and eukaryotic DNA stain DAPI was also used as a co-stain to determine whether DNA is targeted once 4^{4+} internalizes with cells imaged using SIM – Fig. 6.

Visual inspection of images recorded after 10 minutes of exposure indicated that the intracellular accumulation of 4^{4+} and DAPI do not strongly overlap, which is confirmed by a relatively low Pearson's correlation coefficient of 0.28. At 60 minutes there is an increase in co-localization with the Pearson coefficient rising to 0.49. As these data suggest that the complex binds to DNA within SH1000 cells this could result in increased mutational rates. Therefore, a mutagenesis assay (Ames test – fluctuation method) was performed; see ESI.†

These tests reveal that, at concentrations above the MIC, exposure to 4^{4+} results in bacterial DNA damage, providing further evidence that the complex does bind intracellular DNA. However, this effect is less pronounced than that caused by exposure to mutagenic UV-irradiation, suggesting that, above the MIC concentration, DNA damage is only a contributing cause of cell death and is part of a multi-target mechanism of action.

Further co-staining studies with a second imaging probe – the commonly used membrane and cell wall stain NHS-ester 405 – resulted in some revealing results – see ESI.† Initially, co-localization tests between NHS-ester and 4^{4+} show a high correlation; however, co-localization decreases over 60 minutes when there is a concomitant increase in DAPI co-localization. These data suggest that 4^{4+} initially binds to bacterial cell surface regions, then consequently internalizes and increasingly binds to DNA.

Revealingly, when the NHS-ester is added to cells after 4^{4+}, within 20 minutes NHS-ester staining around the periphery of cells becomes discontinuous. After 60 minutes of exposure this discontinuity becomes increasingly prominent – see ESI,† confirming the induction of cell damage.

Many of the observations described above are consistent with our previous research on Gram-negative bacteria, which showed that cell membrane damage occurs on exposure to 4^{4+}. To confirm an analogous mechanism operates in Gram-positive bacteria, the integrity of the *S. aureus* membranes on treatment with 4^{4+} was tested through an ATP release assay. In this assay, cells were exposed to 4^{4+} at its MIC and 0.5 MIC – see ESI.† These experiments showed that treated cells release more ATP than untreated controls. Furthermore, at the MIC concentration a build-up of cellular debris was observed, indicating that cell lysis was occurring.

The effect of 4^{4+} on the membrane potential of *S. aureus* cells was also measured using the membrane potential dye $DiOC_2(3)$ – Fig. 7. In intact bacteria cells $DiOC_2(3)$ emits in the green; however once a membrane is polarized and its potential


Fig. 6 DAPI co-localization SIM experiments. Cells imaged using the emission of 4^{4+} on excitation at 450 nm using the 488 nm laser and the A568 filter (A), emission of DAPI using the 405 nm laser and DAPI filter (B), overlay image (C). After treatment with 4 μM 4^{4+}, cells were incubated with DAPI for 5 minutes and washed with PBS before fixing with paraformaldehyde (4%).


Fig. 7 Detection of membrane potential in *S. aureus* SH100 cells. Red/green cell populations were calculated using population mean fluorescence intensities for *S. aureus* cells incubated with 30 μM $DiOC_2(3)$ for 30 minutes, in the presence or absence of μM of 4^{4+} for 10 minutes. Top: Percentage population is shown in two representation styles. Analysis was conducted using red and green fluorescence parameters. Bottom: The red-*versus* green fluorescence dot plots. Flow cytometer data were collected with log amplification.

increases the emission of $DiOC_2(3)$ undergoes a red shift, due to dye self-association at higher cytosolic concentrations.[70] A diagnostic shift from green to red (red-green) is observed when cells are treated with 4^{4+} at its MIC concentration, signifying an increase in membrane potential. Together, these two experiments provide definitive proof that exposure to 4^{4+} does lead to membrane damage in *S. aureus*.[71,72]

As 4^{4+} contains two electron dense Ru^{II}-centres, it is an excellent contrast stain for Transmission Electron Microscopy (TEM). Therefore, damage to the cell wall and membrane was directly imaged using TEM – Fig. 8.

From these images it is clear the compound causes disruption to both the cell wall and the cell membrane within 20 minutes. At concentrations above its MIC, complex 4^{4+} causes rapid cell death; cell walls appear swollen, and blebbing/channelling is evident. These effects account for the ATP leakage and membrane potential changes seen in the membrane damage assays.

As complex 4^{4+} displays high activity against a wild-type strain and appeared to function through multi-target mechanisms that are analogous to those observed in Gram-negative pathogens, its activity against other *S. aureus* strains was then investigated. This screen involved a clinical isolate strain taken from a patient with septic arthritis and septicaemia and a confirmed MRSA strain BH1CC – Table 3. BH1CC is a *mecA* positive, methicillin resistant strain of *S. aureus*.

In contrast to our work on pathogenic drug resistant Gram-negative bacteria, a significant decrease in activity is observed

Table 3 Comparative MIC (μM) results for SH1000, MRSA and an AMR clinical isolate treated with complex 4^{4+}, in CDM and MH-II

Strain	MH-II	CDM
SH1000	40	4
BH1CC	76.5	38.3
Clinical isolate	51.0	19.1

across both strains in comparison to SH1000. This suggests some strain specific susceptibility against 4^{4+}. The molecular basis for resistance was therefore investigated.

Although the cellular responses of *S. aureus* are similar to those observed for *E. coli*, one noticeable difference is the distinctive punctated, cell-associated pattern of 4^{4+} – in *S. aureus* cell walls, shown in Fig. 4 and 5. This suggests that the initial interaction of the complex with Gram-positive and Gram-negative bacteria is different. This is not surprising – a major difference between these two classes of microorganisms is the composition and structure of their cell walls. To investigate this issue, a series of more specialized experiments were carried out.

One obvious difference between the two classes is that the cell wall of Gram-positive bacteria contains a much thicker outer peptidoglycan layer compared to Gram-negative bacteria. Indeed, the biosynthesis of this structure is the established therapeutic target of both beta-lactam and glycopeptide antibiotics.[73] To ascertain whether this component of the cell wall is a binding target for 4^{4+}, co-staining with a blue emitting peptidoglycan stain – the D-amino acid, HCC-amino-D-alanine (HADA) – was carried out and imaged through SIM, Fig. 9.[74] These experiments revealed that, although some co-localization between the two dyes emerged after 60 minutes exposure, the initial distinctive distribution of 4^{4+} shows little co-localization with HADA; therefore, specific peptidoglycan binding by the complex can be discounted.

A second characteristic feature of cell walls in Gram-positive bacteria is that it is densely functionalized with glycopolymers. The two most common glycopolymers, wall teichoic acid and lipoteichoic acid, contain anionic residues and also moieties that protrude from the cell wall.[75–78] As these structures are known to bind extracellular metal cations, the possibility that they interact with 4^{4+} was then investigated.

To address this question, experiments on two mutant strains of *S. aureus* were carried out. The *tarO* strain is deficient in wall teichoic acids,[79] whilst the *dltA* strain is specifically deficient in D-alanylated teichoic acids.[80]

First, MICs for these two mutants were quantified and compared to the data obtained for the SH1000 wild-type strain – Table 4. These data revealed that both mutant strains possess lower MICs for 4^{4+} than SH1000, indicating that binding to the anionic residues of teichoic acid in the wild-type strain lowers susceptibility to 4^{4+} and prevents the compound from reaching other cellular targets. This hypothesis is consistent with previous studies showing increased synthesis of wall teichoic acid is a known resistance mechanism in *S. aureus*.

Imaging experiments involving the *dltA* mutant were also revealing. Using SIM, the uptake and subsequent localization

Fig. 8 Detection of membrane damage using transmission electron microscopy (TEM). Images were taken at (A) in the absence of compound and at 20 (B), 60 (C) and 120 (D) minutes after exposure to 4^{4+}. In the healthy control the cell wall (CW), plasma membrane (PM) and septum (S) are labelled. Cells were fixed using 2.5% glutaraldehyde in sodium cacodylate buffer (pH 7.4) and stained solely with 4^{4+} (40 μM). The 0 minute control was stained with osmium tetroxide, uranyl acetate and lead citrate.

Fig. 9 Localization of 4^{4+} and HADA in *S. aureus* SH1000 cells visualized through SIM at 10, 20 and 60 minutes. The emission of 4^{4+} upon excitation with the 488 nm laser was collected using the A568 filter (A), emission of HADA from excitation with the 405 nm laser was collected using the DAPI filter (B), overlay image (C). Cells were stained with HADA for 5 minutes prior to incubation with 4^{4+}. After treatment with 4 μM 4^{4+} cells were washed with PBS and fixed with PFA (4%). Co-localisation scatter plots are shown (D). See ESI† for Pearson's correlation coefficient.

Table 4 Comparative MIC (μM) results for SH1000, *tarO*, *dltA* and *mprF* treated with complex 4^{4+} in MH-II

Strain	MIC
SH1000	40
dltA	20
tarO	15
MprF	1.5

pattern produced on exposure to 4^{4+} were compared to SH1000, Fig. 10. In contrast to the wild-type, staining of the *dltA* mutant did not produce a punctated accumulation pattern over the membrane and the septa of dividing cells are not significantly stained by 4^{4+}. Furthermore, although the mutant was exposed to the same concentration of 4^{4+} as the wild-type strain, *dltA* displays brighter luminescence from the internalized complex, suggesting a higher concentration of compound enters the cell. This provides further evidence that binding to teichoic acids within the cell wall of Gram-positive bacteria inhibits cellular internalization and lowers the therapeutic potency of 4^{4+}.

The uptake of 4^{4+} by *dltA* was monitored by measuring Ru content (g) per cell using ICP-AES – see ESI† – Fe content was


Fig. 10 Localization of 4^{4+} in *S. aureus dltA* cells visualized through SIM at 20 min (left) and 60 min (right). Cells imaged using the emission of 4^{4+} on excitation at 450 nm using the A568 filter. After treatment with 4 μM 4^{4+}, cells were washed with PBS before fixing with para-formaldehyde (4%).

also recorded. The experiment was conducted in the absence of glucose to monitor the differences in compound uptake between *dltA* and SH1000. The different profiles suggest a different mechanism of uptake. The intracellular concentration of 4^{4+} at the earlier time-points (5, 10 and 20 min) is higher in the *dltA*; however, the final intracellular compound concentration is similar across both strains. This supports the hypothesis that 4^{4+} binds teichoic acids on the cell membrane preventing optimal intracellular concentrations, thus lowering the activity. In addition, this observation is consistent with the time-kill assays where significant cell death occurs within the first 30 minutes of exposure to 4^{4+}, showing that the higher initial intracellular concentration accounts for the lower MIC in *dltA* cells. Cell viability was monitored through the course of the experiment by CFU mL^{-1} counts and the cells did not lyse.

Along with our previous work on Gram-negative bacteria, the experiments described above demonstrate that exposure of *S. aureus* cells to 4^{4+} causes cell membrane damage and lysis. To confirm this hypothesis and explore another known resistance mechanism available to *S. aureus* we carried out experiments with a third mutant strain, associated with membrane charge.

An established resistance mechanism to membrane active agents in *S. aureus* involves up-regulation of *mprF*.[80] This gene codes for an enzyme that links lysine to negatively charged phosphatidylglycerol and translocates the resulting positively charged lysyl-phosphatidylglycerol to the outer leaflet of the cytoplasmic membrane, a process that increases positive charge on the outer surface of the *S. aureus* membrane and thus reduces susceptibility to cationic antibiotics. Knockout of *mprF* necessitates that the bacterial membrane outer leaflet retains a higher negative charge compared to the wild-type.[81,82] Revealingly, 4^{4+} is considerably more active against this strain than any other tested – Table 4.

Another known mechanism of resistance in MRSA strains is upregulation of teichoic and lipoteichoic acids.[83] To investigate whether this may cause the decrease in activity of 4^{4+} any binding interactions were probed by STED nanoscopy – Fig. 11. It is clear that in the MRSA strain, 4^{4+} does not penetrate the cell wall and membrane. Indeed, the complex is clearly retained on the cell–wall and the previously described spotting

Fig. 11 STED nanoscopy of *S. aureus* BH1CC cells stained with 4^{4+}. Representative images showing section planes of full-volume deconvoluted diffraction-limited cells and super-resolution images (d-LCSM and d-3D STED). Zoomed in areas of the white squares are shown adjacent to the images, as well as the orthogonal representation of every axis (*XY*, *XZ* and *YZ*), where the increased resolution confirms accumulation of 4^{4+} within the cell wall and membrane. Images (i and ii) show the probe distribution at two different sections of the cell, where the higher structural resolution provided by STED at the equatorial and the apical section of the cells is apparent. Inset (iii) shows two adjacent cells, and to right-hand side, 3 different *Z*-planes (87 nm separation between them) again, increased resolution of structural features can be delineated in 3D dSTED images (red). Conditions: after treatment with 4 μM 4^{4+} for 60 minutes, cells were washed with PBS before fixing with paraformaldehyde (4%).

accumulation is noticeably more prevalent. Strikingly in these 3D-STED images the septa of the cell are no longer visible confirming that the complex is not internalized. This supports the hypothesis that the compound is electrostatically binding teichoic and lipoteichoic acids, preventing high concentrations of 4^{4+} within the cell, thus lowering the activity.

Conclusions

Taken together, the studies in this report confirm that two of the therapeutic targets of 4^{4+} in bacteria are their cell membranes and DNA content. Furthermore, the experiments on the mutant strains reveal that the reason the complex is more active against Gram-negative bacteria compared to Gram-positive bacteria is due to intrinsic differences in the molecular structures of these microorganisms.

As discussed above, as has been observed with other antibacterials accretion of cationic lysyl-phosphatidylglycerol residues on the outside of the cytoplasmic membrane inhibits internalization of the complex. Indeed a very recent report on helicates, published as we compiled this study, showed that bacterial resistance to such systems also involves reduction of net negative surface charge.[84] Cell walls densely functionalized with the glycopolymers teichoic acid and lipoteichoic acids also provides an additional barrier to uptake toward 4^{4+}.

Identification of these mechanisms provide new therapeutic opportunities. For example, studies have shown that combinations such as a small molecule *tarO* inhibitor that blocks the production of WTA and a conventional antimicrobial are synthetically lethal to therapeutically resistant bacterial strains.[85,86] Such a strategy will be explored in future work. Furthermore, the identification of resistance mechanisms in *S. aureus* strains has afforded insights into the on-going construction of new molecular architectures, based on 4^{4+}, possessing structural features designed to mitigate the effect of these mechanisms.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Notes and references

1 S. B. Levy and B. Marshall, *Nat. Med.*, 2004, **10**, S122–S129.
2 World Health Organization, *Antimicrobial resistance: global report on surveillance*, 2014.
3 E. Toner, A. Adalja, G. K. Gronvall, A. Cicero and T. V. Inglesby, *Health Security*, 2015, **13**, 153–155.
4 R. Kelly and S. Davies, *Nat. Microbiol.*, 2016, **1**, 16187.
5 E. Tacconelli, E. Carrara, A. Savoldi, S. Harbarth, M. Mendelson, D. L. Monnet, C. Pulcini, G. Kahlmeter, J. Kluytmans, Y. Carmeli, M. Ouellette, K. Outterson, J. Patel, M. Cavaleri, E. M. Cox, C. R. Houchens, M. L. Grayson, P. Hansen, N. Singh, U. Theuretzbacher, N. Magrini, S. S. Al-Abri, N. Awang Jalil, N. Benzonana, S. Bhattacharya, F. R. Burkert, O. Cars, G. Cornaglia, S. Gandra, C. G. Giske, D. A. Goff, M. Guzman Blanco, T. Jinks, S. S. Kanj, L. Kerr, M.-P. Kieny, K. Leder, G. Levy-Hara, J. Littman, S. Malhotra-Kumar, A. Pan, D. L. Paterson, M. Paul, J. Rodríguez-Baño, M. Sanguinetti, S. Sengupta, M. Sharland, M. Si-Mehand, L. L. Silver, G. E. Thwaites, J. W. van der Meer, S. Vega, A. Wechsler-Fördös, N. Woodford, F. O. Yilmaz and A. Zorzet, *Lancet Infect. Dis.*, 2018, **18**, 318–327.
6 A. J. Alanis, *Arch. Med. Res.*, 2005, **36**, 697–705.

7 A. H. Holmes, L. S. P. Moore, A. Sundsfjord, M. Steinbakk, S. Regmi, A. Karkey, P. J. Guerin and L. J. V. Piddock, *Lancet*, 2016, **387**, 176–187.

8 A. R. Brochado, A. Telzerow, J. Bobonis, M. Banzhaf, A. Mateus, J. Selkrig, E. Huth, S. Bassler, J. Zamarreño Beas, M. Zietek, N. Ng, S. Foerster, B. Ezraty, B. Py, F. Barras, M. M. Savitski, P. Bork, S. Göttig and A. Typas, *Nature*, 2018, **559**, 259–263.

9 S. J. Projan, *Curr. Opin. Microbiol.*, 2003, **6**, 427–430.

10 K. M. Overbye and J. F. Barrett, *Drug Discovery Today*, 2005, **10**, 45–52.

11 M. N. Gwynn, A. Portnoy, S. F. Rittenhouse and D. J. Payne, *Ann. N. Y. Acad. Sci.*, 2010, **1213**, 5–19.

12 A. R. White, *J. Antimicrob. Chemother.*, 2011, **66**, 1948–1953.

13 E. D. Brown and G. D. Wright, *Nature*, 2016, **529**, 336–343.

14 M. S. Butler, M. A. Blaskovich and M. A. Cooper, *J. Antibiot.*, 2017, **70**, 3–24.

15 M. J. Renwick, D. M. Brogan and E. Mossialos, *J. Antibiot.*, 2016, **69**, 73–88.

16 M. F. Richter and P. J. Hergenrother, *Chem*, 2017, **3**, 10–13.

17 J. Jampilek, *Curr. Med. Chem.*, 2019, **25**, 4972–5006.

18 C. O. Årdal, D. Findlay, M. Savic, Y. Carmeli and I. Gyssens, *Drive-AB Report: Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access*, 2018.

19 R. Tommasi, D. G. Brown, G. K. Walkup, J. I. Manchester and A. A. Miller, *Nat. Rev. Drug Discovery*, 2015, **14**, 529–542.

20 M. Fridman, *Chem*, 2017, **3**, 8–10.

21 F. P. Dwyer, E. C. Gyarfas, W. P. Rogers and J. H. Koch, *Nature*, 1952, **170**, 190–191.

22 F. P. Dwyer, I. K. Reid, A. Shulman, G. M. Laycock and S. Dixson, *Aust. J. Exp. Biol. Med. Sci.*, 1969, **47**, 203–218.

23 M. Patra, G. Gasser and N. Metzler-Nolte, *Dalton Trans.*, 2012, **41**, 6350–6410.

24 N. Metzler-Nolte, *Curr. Opin. Chem. Biol.*, 2012, **16**, 84–91.

25 L. Viganor, O. Howe, P. McCarron, M. McCann and M. Devereux, *Curr. Top. Med. Chem.*, 2017, **17**, 1280–1302.

26 A. Regiel-Futyra, J. M. Dąbrowski, O. Mazuryk, K. Śpiewak, A. Kyzioł, B. Pucelik, M. Brindell and G. Stochel, *Coord. Chem. Rev.*, 2017, **351**, 76–117.

27 M. A. Sierra, L. Casarrubios and M. C. de la Torre, *Chem.–Eur. J.*, 2019, **25**, 7232–7242.

28 S. E. Howson, A. Bolhuis, V. Brabec, G. J. Clarkson, J. Malina, A. Rodger and P. Scott, *Nat. Chem.*, 2011, **4**, 31–36.

29 M. Wenzel, M. Patra, C. H. R. Senges, I. Ott, J. J. Stepanek, A. Pinto, P. Prochnow, C. Vuong, S. Langklotz, N. Metzler-Nolte and J. E. Bandow, *ACS Chem. Biol.*, 2013, **8**, 1442–1450.

30 A. I. Ramos, T. M. Braga and S. S. Braga, *Mini-Rev. Med. Chem.*, 2012, **12**, 227–235.

31 H. M. Southam, J. A. Butler, J. A. Chapman and R. K. Poole, *Adv. Microb. Physiol.*, 2017, **71**, 1–96.

32 Y. Yang, G. Liao and C. Fu, *Polymers*, 2018, **10**, 650–712.

33 A. Bolhuis, L. Hand, J. E. Marshall, A. D. Richards, A. Rodger and J. Aldrich-Wright, *Eur. J. Pharm. Sci.*, 2011, **42**, 313–317.

34 X. Liu, B. Sun, R. E. M. Kell, H. M. Southam, J. A. Butler, X. Li, R. K. Poole, F. R. Keene and J. G. Collins, *ChemPlusChem*, 2018, **83**, 643–650.

35 A. K. F. Mårtensson, M. Bergentall, V. Tremaroli and P. Lincoln, *Chirality*, 2016, **28**, 713–720.

36 S. V. Kumar, S. Ø. Scottwell, E. Waugh, C. J. McAdam, L. R. Hanton, H. J. L. Brooks and J. D. Crowley, *Inorg. Chem.*, 2016, **55**, 9767–9777.

37 F. O'Reilly, J. Kelly and A. Kirsch-DeMesmaeker, *Chem. Commun.*, 1996, 1013–1014.

38 F. M. O'Reilly and J. M. Kelly, *New J. Chem.*, 1998, **22**, 215–217.

39 J. L. Morgan, C. B. Spillane, J. A. Smith, D. P. Buck, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2007, 4333.

40 Y. Mulyana, D. K. Weber, D. P. Buck, C. A. Motti, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2011, **40**, 1510.

41 F. Li, Y. Mulyana, M. Feterl, J. M. Warner, J. G. Collins and F. R. Keene, *Dalton Trans.*, 2011, **40**, 5032.

42 X. Li, A. K. Gorle, M. K. Sundaraneedi, F. R. Keene and J. G. Collins, *Coord. Chem. Rev.*, 2018, **375**, 134–147.

43 F. Li, E. J. Harry, A. L. Bottomley, M. D. Edstein, G. W. Birrell, C. E. Woodward, F. R. Keene and J. G. Collins, *Chem. Sci.*, 2014, **5**, 685–693.

44 D. K. Weber, M.-A. Sani, M. T. Downton, F. Separovic, F. R. Keene and J. G. Collins, *J. Am. Chem. Soc.*, 2016, **138**, 15267–15277.

45 C. Rajput, R. Rutkaite, L. Swanson, I. Haq and J. A. Thomas, *Chem.–Eur. J.*, 2006, **12**, 4611–4619.

46 M. R. Gill, J. Garcia-Lara, S. J. Foster, C. Smythe, G. Battaglia and J. A. Thomas, *Nat. Chem.*, 2009, **1**, 662–667.

47 A. Wragg, M. R. Gill, D. Turton, H. Adams, T. M. Roseveare, C. Smythe, X. Su and J. A. Thomas, *Chem.–Eur. J.*, 2014, **20**, 14004–14011.

48 A. Wragg, M. R. Gill, C. J. Hill, X. Su, A. J. H. M. Meijer, C. Smythe and J. A. Thomas, *Chem. Commun.*, 2014, **50**, 14494–14497.

49 A. Wragg, M. R. Gill, L. McKenzie, C. Glover, R. Mowll, J. A. Weinstein, X. Su, C. Smythe and J. A. Thomas, *Chem.–Eur. J.*, 2015, **21**, 11865–11871.

50 S. D. Fairbanks, C. C. Robertson, F. R. Keene, J. A. Thomas and M. P. Williamson, *J. Am. Chem. Soc.*, 2019, **141**, 4644–4652.

51 K. L. Smitten, H. M. Southam, J. Bernardino de la Serna, M. R. Gill, P. J. Jarman, C. G. W. Smythe, R. K. Poole and J. A. Thomas, *ACS Nano*, 2019, **13**, 5133–5146.

52 J. Bolger, A. Gourdon, E. N. Ishow and J.-P. Launay, *J. Chem. Soc., Chem. Commun.*, 1995, 1799.

53 K. Sieradzki, R. B. Roberts, S. W. Haber and A. Tomasz, *N. Engl. J. Med.*, 1999, **340**, 517–523.

54 M. C. Enright, D. A. Robinson, G. Randle, E. J. Feil, H. Grundmann and B. G. Spratt, *Proc. Natl. Acad. Sci. U. S. A.*, 2002, **99**, 7687–7692.

55 S. Deresinski, *Clin. Infect. Dis.*, 2005, **40**, 562–573.

56 C. Walsh, *Nature*, 2000, **406**, 775–781.

57 K. Hiramatsu, *Lancet Infect. Dis.*, 2001, **1**, 147–155.

58 F. D. Lowy, *J. Clin. Invest.*, 2003, **111**, 1265–1273.

59 M. N. Alekshun and S. B. Levy, *Cell*, 2007, **128**, 1037–1050.

60 A. J. O'Neill, *Lett. Appl. Microbiol.*, 2010, **51**, 358–361.

61 J. Flatley, J. Barrett, S. T. Pullan, M. N. Hughes, J. Green and R. K. Poole, *J. Biol. Chem.*, 2005, **280**, 10065–10072.

62 G. A. Pankey and L. D. Sabath, *Clin. Infect. Dis.*, 2004, **38**, 864–870.

63 H. E. Kubitschek and J. A. Friske, *J. Bacteriol.*, 1986, **168**, 1466–1467.

64 M. Loferer-Krossbacher, J. Klima and R. Psenner, *Appl. Environ. Microbiol.*, 1998, **64**, 688–694.

65 J. Z. Rappoport, in *Fluorescence Microscopy: Super-Resolution and other Novel Techniques*, Elsevier, 2014, pp. 199–212.

66 L. Schermelleh, A. Ferrand, T. Huser, C. Eggeling, M. Sauer, O. Biehlmaier and G. P. C. Drummen, *Nat. Cell Biol.*, 2018, **21**, 1–13.

67 L. Meyer, D. Wildanger, R. Medda, A. Punge, S. O. Rizzoli, G. Donnert and S. W. Hell, *Small*, 2008, **4**, 1095–1100.

68 G. Vicidomini, G. Moneron, K. Y. Han, V. Westphal, H. Ta, M. Reuss, J. Engelhardt, C. Eggeling and S. W. Hell, *Nat. Methods*, 2011, **8**, 571–573.

69 H. Blom and J. Widengren, *Chem. Rev.*, 2017, **117**, 7377–7427.

70 L. V. Johnson, *J. Cell Biol.*, 1981, **88**, 526–535.

71 A. J. O'Neill and B. Oliva, *J. Antimicrob. Chemother.*, 2004, **54**, 1127–1129.

72 Y. Zhang, X. Chen, C. Gueydan and J. Han, *Cell Res.*, 2018, **28**, 9–21.

73 N. Malanovic and K. Lohner, *Biochim. Biophys. Acta, Biomembr.*, 2016, **1858**, 936–946.

74 E. Kuru, S. Tekkam, E. Hall, Y. V. Brun and M. S. Van Nieuwenhze, *Nat. Protoc.*, 2014, **10**, 33–52.

75 F. C. Neuhaus and J. Baddiley, *Microbiol. Mol. Biol. Rev.*, 2003, **67**, 686–723.

76 C. Weidenmaier and A. Peschel, *Nat. Rev. Microbiol.*, 2008, **6**, 276–287.

77 S. Brown, J. P. Santa Maria Jr and S. Walker, *Annu. Rev. Microbiol.*, 2013, **67**, 313–336.

78 M. G. Percy and A. Gründling, *Annu. Rev. Microbiol.*, 2014, **68**, 81–100.

79 C. Weidenmaier, C. Weidenmaier, A. Peschel, A. Peschel, Y.-Q. Xiong, Y. Q. Xiong, S. A. Kristian, S. A. Kristian, K. Dietz, K. Dietz, M. R. Yeaman, M. R. Yeaman, A. S. Bayer and A. S. Bayer, *J. Infect. Dis.*, 2005, **191**, 1771–1777.

80 M. Gross, S. E. Cramton, F. Gotz and A. Peschel, *Infect. Immun.*, 2001, **69**, 3423–3426.

81 Y. Oku, *Microbiology*, 2004, **150**, 45–51.

82 J. Andrä, T. Goldmann, C. M. Ernst, A. Peschel and T. Gutsmann, *J. Biol. Chem.*, 2011, **286**, 18692–18700.

83 U. Bertsche, C. Weidenmaier, D. Kuehner, S.-J. Yang, S. Baur, S. Wanner, P. Francois, J. Schrenzel, M. R. Yeaman and A. S. Bayer, *Antimicrob. Agents Chemother.*, 2011, **55**, 3922–3928.

84 D. H. Simpson, A. Hapeshi, N. J. Rogers, V. Brabec, G. J. Clarkson, D. J. Fox, O. Hrabina, G. L. Kay, A. K. King, J. Malina, A. D. Millard, J. Moat, D. I. Roper, H. Song, N. R. Waterfield and P. Scott, *Chem. Sci.*, 2019, **8**, 402–413.

85 J. Campbell, A. K. Singh, J. P. Santa Maria Jr, Y. Kim, S. Brown, J. G. Swoboda, E. Mylonakis, B. J. Wilkinson and S. Walker, *ACS Chem. Biol.*, 2010, **6**, 106–116.

86 L. Pasquina, J. P. Santa Maria, B. McKay Wood, S. H. Moussa, L. M. Matano, M. Santiago, S. E. S. Martin, W. Lee, T. C. Meredith and S. Walker, *Nat. Chem. Biol.*, 2015, **12**, 40–45.